Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2016 - 2025)

Ani Pharmaceuticals' Amortization of Deferred Charges history spans 12 years, with the latest figure at $351000.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 8.67% year-over-year to $351000.0; the TTM value through Dec 2025 reached $1.4 million, up 111.21%, while the annual FY2025 figure was $1.4 million, 111.21% up from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $351000.0 at Ani Pharmaceuticals, up from $340000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.2 million in Q4 2022 and bottomed at -$196000.0 in Q3 2022.
  • The 5-year median for Amortization of Deferred Charges is $570500.0 (2021), against an average of $599800.0.
  • The largest annual shift saw Amortization of Deferred Charges plummeted 133.97% in 2022 before it soared 1012.24% in 2023.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $794000.0 in 2021, then surged by 175.57% to $2.2 million in 2022, then plummeted by 56.49% to $952000.0 in 2023, then crashed by 66.07% to $323000.0 in 2024, then grew by 8.67% to $351000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Amortization of Deferred Charges are $351000.0 (Q4 2025), $340000.0 (Q3 2025), and $341000.0 (Q2 2025).